Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
AQST
Aquestive Therapeutics, Inc.
Anaphylm's oral small-molecule epinephrine film and AQST-108 (epinephrine topical gel) indicate a focus on oral small-molecule therapeutics delivered via film/topical formats.
|
$620.28M |
$6.21
+1.97%
|
|
CBLL
CeriBell, Inc.
Ceribell's core product is a point-of-care diagnostic EEG system (diagnostic equipment).
|
$619.99M |
$16.89
-2.65%
|
|
SRDX
Surmodics, Inc.
Surmodics' vascular intervention devices (SurVeil DCB, Pounce thrombectomy, Sublime radial access) are a core product category sold by the company.
|
$614.58M |
$42.98
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$612.32M |
$11.32
-1.91%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$610.02M |
$2.25
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$589.53M |
$11.05
+0.96%
|
|
TCMD
Tactile Systems Technology, Inc.
Core medical devices for lymphedema and airway clearance (Flexitouch Plus, Nimbl, AffloVest) are manufactured and sold by the company.
|
$578.04M |
$25.93
-0.52%
|
|
TALK
Talkspace, Inc.
Talkspace is a behavioral health services provider delivering therapy to patients and payer networks.
|
$571.06M |
$3.42
+2.09%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$561.45M |
$10.43
-0.67%
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$550.05M |
$33.26
+10.98%
|
|
AVNS
Avanos Medical, Inc.
Avanos produces surgical equipment including radiofrequency ablation (RFA) systems and related devices used in procedures.
|
$549.41M |
$11.86
-0.96%
|
|
LAB
Standard BioTools Inc.
SomaScan laboratory testing and advisory services are a core direct offering.
|
$546.25M |
$1.43
+0.35%
|
|
NPCE
NeuroPace, Inc.
Core product Neuromodulation device (RNS System) delivering brain-responsive, on-demand therapy for drug-resistant epilepsy.
|
$545.84M |
$16.53
-1.02%
|
|
ASPI
ASP Isotopes Inc. Common Stock
ASPI’s PET Labs Radiopharmaceuticals production and enriched isotopes are delivered as a core product line.
|
$544.13M |
$5.92
-1.25%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$539.31M |
$9.12
+4.76%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR is pursuing oncology-focused assets (MNPR-101 radiopharmaceuticals) and monoclonal antibody–based therapies, aligning with Biotech - Oncology.
|
$539.01M |
$87.19
-1.45%
|
|
IMAB
I-Mab
I-Mab develops monoclonal antibody therapeutics, including uliledlimab (CD73 antibody) and other antibody-based assets.
|
$533.68M |
$4.64
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$533.60M |
$9.40
-0.11%
|
|
ZIMV
ZimVie Inc.
Prosthetics & Implants—core product line includes dental implants and related prosthetic solutions.
|
$530.23M |
$18.99
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Company is focused on AAV-based gene therapies (LX2006, LX2020) delivering therapeutic genes — direct Gene Therapy business.
|
$520.03M |
$9.63
-0.93%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$519.66M |
$1.44
+1.77%
|
|
NUS
Nu Skin Enterprises, Inc.
The Prysm iO and related wellness devices involve medical/biometric device technology.
|
$515.27M |
$10.39
+2.72%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$513.26M |
$10.99
+2.90%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$506.63M |
$7.32
+6.55%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$501.77M |
$5.23
+0.58%
|
|
ANGO
AngioDynamics, Inc.
Core product category: vascular intervention devices, including Auryon, AlphaVac, and AngioVac.
|
$499.80M |
$12.30
-0.81%
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$499.27M |
$3.71
-0.13%
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$487.12M |
$4.35
-0.91%
|
|
CYH
Community Health Systems, Inc.
CYH directly provides hospital inpatient and outpatient care services through a network of hospitals and related facilities.
|
$483.41M |
$3.46
-0.29%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra focuses on rare-disease therapeutics (NPC, UCD, VEDS) and related pipeline assets, core to rare disease biotech.
|
$482.76M |
$8.60
+2.32%
|
Showing page 17 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
